Hj. Lenz et al., P53 POINT MUTATIONS AND THYMIDYLATE SYNTHASE MESSENGER-RNA LEVELS IN DISSEMINATED COLORECTAL-CANCER - AN ANALYSIS OF RESPONSE AND SURVIVAL, Clinical cancer research, 4(5), 1998, pp. 1243-1250
Recent studies suggest that there may be a strong correlation between
the p53 status of a tumor and a patient's response to chemotherapy, Th
erefore, we determined p53 status in 36 patients with disseminated col
orectal cancer by cDNA sequencing and immunohistochemical staining, as
well as by the gene expression level of thymidylate synthase (TS), th
e target enzyme of 5-fluorouracil (5-FU), by reverse transcription-PCR
, Ten patients (28%) experienced a clinical response to 5-FU chemother
apy, Overall, TS expression and response to chemotherapy were associat
ed: 9 of 18 (50%) patients with TS less than or equal to 3.0 x 10(-3)
responded, compared to 1 of 18 (6%) patients with TS less than or equa
l to 3.0 x 10(-3) (P = 0.003), p53 mutations were found in 21 of 36 pa
tients (58%) using cDNA cycle sequencing, and p53 protein overexpressi
on was found in 20 of 32 patients (62%) using immunohistochemistry sta
ining. Overall p53 status and response to chemotherapy were associated
: 5 of 10 (50%) patients with wildtype p53 or negative p53 staining ex
perienced a response, but only 5 of 26 (19%) patients with mutant p53
or p53 overexpression responded. TS expression, but not expression of
p53, was significantly associated with overall survival (P = 0.002), P
atients with wild-type p53 had significantly lower TS levels compared
to patients with mutated p53 (P = 0.044), In this study, we also prese
nt data linking specific p53 point mutations to TS expression levels a
nd resistance to 5-FU, Although the number of patients is relatively s
mall, these results identify p53 status and TS gene expression as asso
ciated with response in disseminated colorectal cancer; independent st
udies are needed to confirm these findings and to provide information
leading to a better understanding of the role of 5-FU-based chemothera
py in the treatment of colorectal cancer.